Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
Submission based on results from pivotal phase III trial showing all primary endpoints met
This approval has come from the company's finished dosage form manufacturing facility
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
First of its kind interactive concept store ‘Brilliant Sound Galaxy (BSG)’ in the capital city
It is a novel oral NLRP3 inflammasome inhibitor
Subscribe To Our Newsletter & Stay Updated
